Blood Res 2022; 57(1):
Published online March 31, 2022
https://doi.org/10.5045/br.2021.2021152
© The Korean Society of Hematology
Correspondence to : Youngil Koh, M.D., Ph.D.
Jun Ho Jang, M.D., Ph.D.
Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea(Y.K.)
Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea (J.H.J.)
E-mail: Y.K., go01@snu.ac.kr
J.H.J., smcjunhojang@gmail.com
*The sequencing study involving Korean patients included in this article was supported by Celgene-BMS.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The mutational and epigenetic landscape of acute myeloid leukemia (AML) has become increasingly well understood in recent years, informing on biological targets for precision medicine. Among the most notable findings was the recognition of mutational hot-spots in the isocitrate dehydrogenase (IDH) genes. In this review, we provide an overview on the IDH1/2 mutation landscape in Korean AML patients, and compare it with available public data. We also discuss the role of IDH1/2 mutations as biomarkers and drug targets. Taken together, occurrence of IDH1/2 mutations is becoming increasingly important in AML treatment, thus requiring thorough examination and follow-up throughout the clinical course of the disease.
Keywords Acute myeloid leukemia, IDH, Biomarker, Drug target, Korean
Blood Res 2022; 57(1): 13-19
Published online March 31, 2022 https://doi.org/10.5045/br.2021.2021152
Copyright © The Korean Society of Hematology.
Ja Min Byun1,2, Seung-Joo Yoo1,2, Hyeong-Joon Kim3, Jae-Sook Ahn3, Youngil Koh1,2, Jun Ho Jang4, Sung-Soo Yoon1,2
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, 3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, 4Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to:Youngil Koh, M.D., Ph.D.
Jun Ho Jang, M.D., Ph.D.
Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea(Y.K.)
Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea (J.H.J.)
E-mail: Y.K., go01@snu.ac.kr
J.H.J., smcjunhojang@gmail.com
*The sequencing study involving Korean patients included in this article was supported by Celgene-BMS.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The mutational and epigenetic landscape of acute myeloid leukemia (AML) has become increasingly well understood in recent years, informing on biological targets for precision medicine. Among the most notable findings was the recognition of mutational hot-spots in the isocitrate dehydrogenase (IDH) genes. In this review, we provide an overview on the IDH1/2 mutation landscape in Korean AML patients, and compare it with available public data. We also discuss the role of IDH1/2 mutations as biomarkers and drug targets. Taken together, occurrence of IDH1/2 mutations is becoming increasingly important in AML treatment, thus requiring thorough examination and follow-up throughout the clinical course of the disease.
Keywords: Acute myeloid leukemia, IDH, Biomarker, Drug target, Korean
Hee Sue Park
Blood Res 2024; 59():Saba Manoochehrabadi, Morteza Talebi, Hossein Pashaiefar, Soudeh Ghafouri‑Fard, Mohammad Vaezi, Mir Davood Omrani and Mohammad Ahmadvand
Blood Res 2024; 59():Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo
Blood Res 2023; 58(4): 181-186